Effects of anti–IL-6 antibody treatment on BLPD
| Patient . | Time from transplantation to BLPD onset (mo) . | Anti–IL-6 treatment/bolus (mg/kg) . | Serum IL-6 level (at day 0) (pg/mL) . | Serum IL-6 level 60 days after treatment (pg/mL) . | Effect on BLPD 4 mo after treatment . | General outcome . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | 6 | No/0.4 | < 1 | 3 | CR | Died (36 mo) of chronic rejection | — |
| 2-a3-150 | 84 | No/0.4 | < 1 | < 1 | PR | Relapse | — |
| 2-b | 90 | No/0.4 | < 1 | — | PD | Died (7 mo) of BLPD | — |
| 3 | 108 | No/0.4 | ND | ND | CR | A&W, CR | 33 |
| 4 | 60 | Yes/0.4 | ND | ND | PD | Anti–IL-6 antibody treatment failure A&W, CR after chemotherapy | 26 |
| 5 | 2 | Yes/0.4 | 9 | < 1 | CR | Died (10 mo) of chronic rejection | — |
| 6 | 6 | Yes/0.8 | 13 | < 1 | CR | Died (13 mo) of liver hilum necrosis | — |
| 7 | 156 | Yes/0.8 | < 1 | ND | PD | Failed anti–IL-6 antibody treatment, A&W, CR after chemotherapy | 22 |
| 8 | 3.5 | Yes/0.8 | 58 | 15 | CR | A&W, CR | 21 |
| 9 | 3.5 | Yes/0.8 | 46 | < 1 | PR | A&W, CR after surgery and retransplantation | 21 |
| 10 | 84 | Yes/0.8 | 15 | — | PD | Died (1 mo) of BLPD | — |
| 11 | 5 | Yes/0.8 | ND | ND | SD | Anti–IL-6 antibody treatment failure, A&W, CR after surgery | 19 |
| 12 | 1 | Yes/0.8 | ND | ND | PR | A&W, PR | 9 |
| Patient . | Time from transplantation to BLPD onset (mo) . | Anti–IL-6 treatment/bolus (mg/kg) . | Serum IL-6 level (at day 0) (pg/mL) . | Serum IL-6 level 60 days after treatment (pg/mL) . | Effect on BLPD 4 mo after treatment . | General outcome . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|
| 1 | 6 | No/0.4 | < 1 | 3 | CR | Died (36 mo) of chronic rejection | — |
| 2-a3-150 | 84 | No/0.4 | < 1 | < 1 | PR | Relapse | — |
| 2-b | 90 | No/0.4 | < 1 | — | PD | Died (7 mo) of BLPD | — |
| 3 | 108 | No/0.4 | ND | ND | CR | A&W, CR | 33 |
| 4 | 60 | Yes/0.4 | ND | ND | PD | Anti–IL-6 antibody treatment failure A&W, CR after chemotherapy | 26 |
| 5 | 2 | Yes/0.4 | 9 | < 1 | CR | Died (10 mo) of chronic rejection | — |
| 6 | 6 | Yes/0.8 | 13 | < 1 | CR | Died (13 mo) of liver hilum necrosis | — |
| 7 | 156 | Yes/0.8 | < 1 | ND | PD | Failed anti–IL-6 antibody treatment, A&W, CR after chemotherapy | 22 |
| 8 | 3.5 | Yes/0.8 | 58 | 15 | CR | A&W, CR | 21 |
| 9 | 3.5 | Yes/0.8 | 46 | < 1 | PR | A&W, CR after surgery and retransplantation | 21 |
| 10 | 84 | Yes/0.8 | 15 | — | PD | Died (1 mo) of BLPD | — |
| 11 | 5 | Yes/0.8 | ND | ND | SD | Anti–IL-6 antibody treatment failure, A&W, CR after surgery | 19 |
| 12 | 1 | Yes/0.8 | ND | ND | PR | A&W, PR | 9 |
The sensitivity of ELISA test for IL-6 is 0.6 pg/mL. Levels indicated as < 1 pg/mL mean that no IL-6 could be detected by this ELISA test. When measured by this method, IL-6 levels in healthy controls were < 1 pg/mL.
ND indicates not done; A&W, alive and well.
2-a and 2-b indicate the first and second course of anti–IL-6 antibody.